A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PCV13

Search Conditions:
Search Keyword : PCV13
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PCV13
Appearance Frequency: 52 time(s)
Long forms: 27

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
pneumococcal conjugate vaccine 13
(16 times)
Communicable Diseases
(5 times)
IPD (5 times)
PPSV23 (2 times)
CI (1 time)
2010 Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
pneumococcal 13-valent conjugate vaccine
(9 times)
Microbiology
(2 times)
IPD (4 times)
PCVs (2 times)
AOM (1 time)
2011 Characterization of highly antimicrobial-resistant clinical pneumococcal isolates recovered in a Chinese hospital during 2009-2010.
pneumococcal conjugate vaccine (Prevenar 13(), Prevnar 13())
(2 times)
Drug Therapy
(2 times)
ACIP (1 time)
CAP (1 time)
IPD (1 time)
2013 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.
pneumococcal vaccine Prevenar 13
(2 times)
Therapeutics
(1 time)
COPD (1 time)
PCV7 (1 time)
2013 Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
13-valent-polysaccharide-pneumococcal-conjugate vaccine
(1 time)
Sexually Transmitted Diseases
(1 time)
EM (1 time)
2017 Erythema multiforme following pneumococcal vaccination.
non-PCV13 serotypes in the late vaccination
(1 time)
Communicable Diseases
(1 time)
CC (1 time)
GNRCS (1 time)
IPD (1 time)
2015 Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.
particularly since the introduction of the 13-valent vaccine
(1 time)
PCOMP (1 time)
2018 Trends in Pediatric Complicated Pneumonia in an Ontario Local Health Integration Network.
Patients received one dose of 13-valent conjugate vaccine
(1 time)
Allergy and Immunology
(1 time)
--- 2015 Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with beta-thalassemia major.
PCV 13-valent
(1 time)
Communicable Diseases, Emerging
(1 time)
ICER (1 time)
PCV10 (1 time)
PCV7 (1 time)
2014 Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
10  PCV10 or the 13-valent vaccine
(1 time)
Science
(1 time)
--- 2013 Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
11  PCV13-7
(1 time)
Epidemiology
(1 time)
IPD (1 time)
NVTs (1 time)
PCVs (1 time)
2017 The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?
12  PCV7 that were included in the new 13-valent
(1 time)
Allergy and Immunology
(1 time)
CI (1 time)
RR (1 time)
2016 Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
13  PCVs, especially 13-valent
(1 time)
Allergy and Immunology
(1 time)
PCVs (1 time)
PDs (1 time)
2014 Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?
14  pfPCV13
(1 time)
Otolaryngology
(1 time)
AOM (1 time)
MyfA (1 time)
pfPCV7 (1 time)
2017 Influence of pneumococcal conjugate vaccines on acute otitis media in Japan.
15  PHiD-CV, or 13-valent PCV
(1 time)
Allergy and Immunology
(1 time)
PCVs (1 time)
2017 Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
16  pneumococcal conjugate 13-valent vaccine
(1 time)
Allergy and Immunology
(1 time)
ICERs (1 time)
LILACS (1 time)
2018 Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.
17  pneumococcal disease incidence, and the 13-valent vaccine
(1 time)
Allergy and Immunology
(1 time)
IPD (1 time)
2010 Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
18  pneumococcal vaccine 13-valent
(1 time)
Vaccines
(1 time)
--- 2016 Evaluating the costs and benefits of pneumococcal vaccination in adults.
19  pneumococcal vaccine-13
(1 time)
Vaccines
(1 time)
--- 2016 Nasopharyngeal pneumococcal carriage rates among HIV-infected adults following widespread pediatric use of conjugate pneumococcal vaccine-13.
20  pneumoniae vaccination using the 13-valent conjugate vaccine
(1 time)
Communicable Diseases
(1 time)
BM (1 time)
GBS (1 time)
RT-PCR (1 time)
2019 Pediatric meningitis due to Neisseria meningitidis, Streptococcus pneumoniae and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018.
21  polysaccharide conjugate vaccine (13-valent, adsorbed)
(1 time)
Geriatrics
(1 time)
--- 2012 Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults.
22  polysaccharide conjugate vaccine Prevenar 13
(1 time)
Pharmacology
(1 time)
--- 2010 Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].
23  population before and after introduction of the 13-valent conjugte vaccine
(1 time)
Medicine
(1 time)
IPD (1 time)
SG (1 time)
ST (1 time)
2020 The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old.
24  Portugal in mid-2009 and the 13-valent vaccine
(1 time)
Communicable Diseases
(1 time)
IPD (1 time)
2014 Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.
25  PPV23 vaccine and the 13-valent conjugate vaccine
(1 time)
Communicable Diseases
(1 time)
HIV (1 time)
IPD (1 time)
PPV23 (1 time)
2013 Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination.
26  programme in 2006 and replaced with a 13-valent vaccine
(1 time)
Allergy and Immunology
(1 time)
IPD (1 time)
VE (1 time)
2019 Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
27  programme switched from a 13-valent
(1 time)
Allergy and Immunology
(1 time)
AOM (1 time)
2019 Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium.